{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:28:28Z","timestamp":1787610508501,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study evaluated whether one (or more) of three doses of onabotulinumtoxinA were safe and effective to treat neurogenic detrusor overactivity (NDO) in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a 48\u2010week prospective, multicenter, randomized, double\u2010blind study in children (aged 5\u201317\u2009years) with NDO and urinary incontinence (UI) receiving one onabotulinumtoxinA treatment (50, 100, or 200\u2009U; not to exceed 6\u2009U\/kg). Primary endpoint: change from baseline in daytime UI episodes. Secondary endpoints: change from baseline in urine volume at first morning catheterization, urodynamic measures, and positive response on the treatment benefit scale. Safety was also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was a similar reduction in urinary incontinence from baseline to Week 6 for all doses (\u22121.3 episodes\/day). Most patients reported positive responses on the treatment benefit scale (75.0%\u221280.5%). From baseline to Week 6, increases were observed in urine volume at first morning clean intermittent catheterization (50\u2009U, 21.9\u2009ml; 100\u2009U, 34.9\u2009ml; 200\u2009U, 87.5\u2009ml; <jats:italic>p<\/jats:italic>\u2009=\u20090.0055, 200\u2009U vs. 50\u2009U) and in maximum cystometric capacity (range 48.6\u221263.6\u2009ml) and decreases in maximum detrusor pressure during the storage phase (50\u2009U, \u221212.9; 100\u2009U, \u221220.1; 200\u2009U, \u221227.3\u2009cmH<jats:sub>2<\/jats:sub>O; <jats:italic>p<\/jats:italic>\u2009=\u20090.0157, 200\u2009U vs. 50\u2009U). The proportion of patients experiencing involuntary detrusor contractions dropped from baseline (50\u2009U, 94.4%; 100\u2009U, 88.1%; 200\u2009U, 92.6%) to Week 6 (50\u2009U, 61.8%; 100\u2009U, 44.7%; 200\u2009U, 46.4%). Safety was similar across doses; urinary tract infection was most frequent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>OnabotulinumtoxinA was well tolerated and effective for the treatment of NDO in children; 200\u2009U showed greater efficacy in reducing bladder pressure and increasing bladder capacity.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.24588","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T10:27:07Z","timestamp":1607682427000},"page":"493-501","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-9524","authenticated-orcid":false,"given":"Paul F.","family":"Austin","sequence":"first","affiliation":[{"name":"Texas Children's Hospital Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-873X","authenticated-orcid":false,"given":"Israel","family":"Franco","sequence":"additional","affiliation":[{"name":"Yale New Haven Children's Hospital New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Dobremez","sequence":"additional","affiliation":[{"name":"H\u00f4pital Pellegrin Enfants Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kroll","sequence":"additional","affiliation":[{"name":"Neuro\u2010urology Unit Paediatric Urology Clinic Pozna\u0144 Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Titanji","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Geib","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet B.","family":"Hoebeke","sequence":"additional","affiliation":[{"name":"Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22376"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/816274"},{"key":"e_1_2_8_4_1","first-page":"85","article-title":"Neurogenic bladder in spinal cord injury patients","volume":"7","author":"Al Taweel W","year":"2015","journal-title":"Res Rep Urol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/145749691110000405"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1745.85707"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2009.01.005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3171\/2010.3.FOCUS1079"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310100741"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-018-0645-z"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2010.03.004"},{"key":"e_1_2_8_12_1","unstructured":"Tekg\u00fclS DoganHS ErdemE et al.Guidelines on Paediatric Urology; 2015.https:\/\/uroweb.org\/wp-content\/uploads\/23-Paediatric-Urology_LR_full.pdf. Accessed November 11 2019."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22247"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.01.074"},{"issue":"94","key":"e_1_2_8_15_1","first-page":"e1\u2010e6","article-title":"Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children","volume":"12","author":"Greer T","year":"2016","journal-title":"J Pediatr Urol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)32480-1"},{"key":"e_1_2_8_17_1","unstructured":"Allergan. Highlights of prescribing information BOTOX (ionabotulinumtoxinA) for injection for intramuscular intradetrusor or intradermal use; 2018.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103000s5307lbl.pdf. Accessed November 11 2019."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23025"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.05.033"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22783"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23124"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23729"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.187.3.8497634"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.056"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2010.07.002"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.24588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.24588","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.24588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T03:39:57Z","timestamp":1693107597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.24588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1002\/nau.24588"],"URL":"https:\/\/doi.org\/10.1002\/nau.24588","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"2020-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}